These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11725178)

  • 1. Assessment of preclinical target organ damage in hypertension: left ventricular hypertrophy.
    Rosei EA
    J Hypertens; 2001 Dec; 19(12):2288-90. PubMed ID: 11725178
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessment of preclinical target organ damage in hypertension: left ventricular hypertrophy.
    Rosei EA;
    J Hypertens; 2002 Jan; 20(1):156-8. PubMed ID: 11791040
    [No Abstract]   [Full Text] [Related]  

  • 3. Assessment of preclinical target organ damage in hypertesion: left ventricular hypertrophy.
    Rosei EA
    Blood Press; 2003; 12(3):183-4. PubMed ID: 12875482
    [No Abstract]   [Full Text] [Related]  

  • 4. Regression of left ventricular hypertrophy in hypertension--does it reduce cardiovascular risk?
    Braz Nogueira J
    Rev Port Cardiol; 2005; 24(7-8):1007-13. PubMed ID: 16240686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of diastolic dysfunction in hypertensive left ventricular hypertrophy.
    Bella JN
    Am J Hypertens; 2006 Sep; 19(9):937-8. PubMed ID: 16942936
    [No Abstract]   [Full Text] [Related]  

  • 6. [The effect of long-term uncontrolled antihypertensive therapy on the echocardiographic signs of left-heart hypertrophy in patients with mild and moderate arterial hypertension].
    Lerman OV; Metelitsa VI; Filatova NP; Duda SG; Malysheva NV; Vygodin VA
    Ter Arkh; 1997; 69(1):43-6. PubMed ID: 9163049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Masked hypertension and target organ damage in treated hypertensive patients.
    Tomiyama M; Horio T; Yoshii M; Takiuchi S; Kamide K; Nakamura S; Yoshihara F; Nakahama H; Inenaga T; Kawano Y
    Am J Hypertens; 2006 Sep; 19(9):880-6. PubMed ID: 16942927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension.
    Pierdomenico SD; Lapenna D; Cuccurullo F
    Am J Hypertens; 2008 Apr; 21(4):464-70. PubMed ID: 18369364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Is it rational to supplement the concept of "target organ" with a category "dynamic target"?].
    Sidorenko GI
    Kardiologiia; 2009; 49(2):73-5. PubMed ID: 19254222
    [No Abstract]   [Full Text] [Related]  

  • 10. Hypertension and left ventricular hypertrophy: what is the link?
    Arthur A; McNulty CM
    R I Med; 1993 May; 76(5):245-8. PubMed ID: 8518500
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects on left ventricular mass and function of low doses of enalapril for systemic hypertension.
    González-Juanatey JR; Reino AP; García-Acuña JM; Varela Román A; Calvo Gómez C; Cabezas-Cerrato J
    Am J Cardiol; 1998 Jan; 81(1):87-90. PubMed ID: 9462614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment.
    Muiesan ML; Salvetti M; Rizzoni D; Castellano M; Donato F; Agabiti-Rosei E
    J Hypertens; 1995 Oct; 13(10):1091-5. PubMed ID: 8586800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Left ventricular hypertrophy in hypertension.
    Dunn FG; Pfeffer MA
    N Engl J Med; 1999 Apr; 340(16):1279-80. PubMed ID: 10210713
    [No Abstract]   [Full Text] [Related]  

  • 14. Left ventricular hypertrophy and hypertension.
    Mancia G
    Eur Heart J; 1996 Jan; 17(1):7-8. PubMed ID: 8682133
    [No Abstract]   [Full Text] [Related]  

  • 15. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).
    Müller-Brunotte R; Kahan T; Malmqvist K; Ring M; Edner M
    Am J Hypertens; 2006 Sep; 19(9):927-36. PubMed ID: 16942935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypertension and left ventricular hypertrophy.
    Krzesinski JM; Rorive G; Van Cauwenberge H
    Acta Cardiol; 1996; 51(2):143-54. PubMed ID: 8742911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertensive heart disease--significance of left ventricular hypertrophy.
    Schmieder RE
    J Cardiovasc Pharmacol; 1992; 20 Suppl 6():S50-5. PubMed ID: 1283190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomics of left ventricular hypertrophy reversal: beyond the 'one size fits all' approach to antihypertensive therapy.
    Schillaci G
    J Hypertens; 2004 Dec; 22(12):2273-5. PubMed ID: 15614020
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical importance of detecting exaggerated blood pressure response to exercise on antihypertensive therapy.
    Mizuno R; Fujimoto S; Saito Y; Yamazaki M
    Heart; 2016 Jun; 102(11):849-54. PubMed ID: 26839069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistant hypertension and left ventricular hypertrophy: an overview.
    Cuspidi C; Vaccarella A; Negri F; Sala C
    J Am Soc Hypertens; 2010; 4(6):319-24. PubMed ID: 21130978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.